Gibson Christopher 4

What Happened Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), converted derivative holdings into common stock and sold 40,000 shares in an open-market transaction on March 23, 2026. The shares sold were disposed at $3.25 each, generating $130,000 in proceeds. The conversion entries (40,000 shares acquired at $0.00 and a corresponding 40,000-share derivative disposition at $0.00) reflect the conversion of derivative securities into shares (see footnote F1).

Key Details

• Transaction date: March 23, 2026. Sale price: $3.25 per share; total proceeds $130,000.
• Conversions: Two derivative conversion entries (40,000 shares acquired at $0.00; 40,000 shares disposed at $0.00) indicate conversion of derivative holdings to common shares (F1).
• Sale execution: Open-market sale pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025 (F2).
• Shares owned after transaction: Not specified in the provided summary—see the full Form 4 for aggregate holdings and post-transaction totals.
• Other footnotes note ownership through family entities/LLCs (F3–F5) and various option vesting schedules (F6–F10) unrelated to this immediate sale.
• Filing: Report filed March 25, 2026 (two days after the trade date), which appears timely under Form 4 rules.

Context This was a sale (a disposition) rather than a purchase—sales may be routine or for liquidity and, in this case, were carried out under a pre-arranged 10b5-1 plan (F2), which typically schedules trades in advance. The conversion entries are not a cash purchase; they reflect conversion of derivative securities (e.g., Class B to Class A per F1) into tradable shares that were then sold. For full details on holdings and any option vesting referenced in the footnotes, consult the complete Form 4 filing.